New evidence
A three-month, 1200 mg/day turmeric supplement significantly reduced TBP2 and NF-κB p65 levels in type 2 diabetes (both P < 0.001) — but this is the first trial to examine that specific pairing, so the evidence is still preliminary.
This is the first randomized controlled trial to show that turmeric can lower thioredoxin-binding protein-2 (TBP2) and a key inflammatory driver (NF-κB) in people with type 2 diabetes. Because it’s a single study in a clinical population with undisclosed funding, the results are a promising lead — not a settled recommendation.
TBP2 is a protein that blocks the body’s main antioxidant system, while NF-κB is a master switch for inflammation. By reducing both, turmeric may help protect blood vessels and nerves from diabetic damage. The study also found improvements in neuropathy symptoms and other vascular markers, but all findings come from one trial; replication is needed before drawing broad conclusions.
Where this fits in the evidence
This is among the first studies we've indexed on Turmeric for Reduced Thioredoxin-Binding Protein-2 Level — treat it as an early signal until more research accumulates.
The study
- Randomized Controlled Trial (RCT)
- 2026-04
- European journal of nutrition
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.